Celldex Therapeutics, Inc. — Q2 2013 Form 10-Q
Reporting period: Three and six months ended June 30, 2013; filed August 6, 2013. Celldex is a clinical-stage biopharmaceutical company developing immunotherapies and antibody-drug conjugates. Financial statements are unaudited. Unless noted, figures below are in U.S. dollars.
Financial results and position
| Metric | Q2 2013 | Q2 2012 | Six months 2013 | Six months 2012 |
|---|---|---|---|---|
| Total revenue | $0.10 million | $2.01 million | $2.51 million | $4.44 million |
| Research and development expense | $15.09 million | $11.11 million | $29.18 million | $21.88 million |
| General and administrative expense | $3.41 million | $2.22 million | $6.55 million | $4.54 million |
| Operating loss | $18.66 million | $13.49 million | $36.06 million | $26.78 million |
| Net loss | $19.02 million | $13.77 million | $36.35 million | $27.29 million |
| Basic and diluted loss per share | $0.24 | $0.23 | $0.47 | $0.50 |
- Revenue is largely non-recurring in the periods shown. Product royalties were zero in Q2 2013 versus $1.87 million in Q2 2012; six-month royalties fell to $2.33 million from $4.22 million. The company said the Rotarix agreement had terminated upon expiration of the relevant patent rights and it did not expect further related royalty revenue or expense.
- At June 30, cash and cash equivalents were $25.9 million and marketable securities were $129.1 million, totaling $155.0 million. Working capital was $143.9 million. Total assets were $196.2 million and stockholders’ equity was $177.1 million.
- Six-month operating cash use was $35.3 million, compared with $25.5 million in 2012. Investing activities used $69.2 million, primarily reflecting net purchases of marketable securities; financing activities provided $105.4 million, mainly from stock issuance.
- The $15 million term loan was prepaid in May 2013; no term loan remained at June 30. Celldex paid $8.8 million in principal and $0.7 million in interest and prepayment/final fees, and released the associated security interests. Other long-term liabilities were $6.6 million.
- Revenue is immaterial relative to research and development spending, and the company reported operating and net losses. A conventional operating margin is not meaningful in this context.
Material changes and operating developments
- Q2 net loss increased $5.2 million year over year; the six-month loss increased $9.1 million. Management attributed the increases primarily to higher R&D and G&A spending.
- Six-month R&D expense increased 33%, driven mainly by clinical-trial and contract-manufacturing costs, particularly for rindopepimut. Rindopepimut program R&D spending was $17.7 million versus $11.0 million a year earlier. G&A rose 44%, including higher headcount, professional services, and commercial planning.
- Common shares issued and outstanding increased to 80.98 million at June 30 from 64.36 million at year-end 2012. Six-month equity proceeds included $97.0 million net from an underwritten offering and $17.1 million net under the Cantor sales agreement.
- Celldex planned to initiate METRIC, a randomized study of CDX-011 in triple-negative breast cancer with GPNMB over-expression, in the second half of 2013. It expected ACT IV rindopepimut enrollment to finish by year-end 2013, with data anticipated 18–24 months after enrollment completion. Preliminary CDX-1135 data were expected by year-end 2013; CDX-1127 solid-tumor data were also anticipated by year-end.
Outlook, risks, and contingencies
- Management said available cash, cash equivalents, and marketable securities were sufficient to fund planned operations for at least 12 months; the MD&A separately stated that resources were expected to fund planned operations through 2015. These are management estimates, not a guarantee of runway.
- Celldex expected operating cash use to increase over the next 12 months, principally due to rindopepimut and CDX-011 programs. It anticipated higher R&D spending for clinical trials and manufacturing and higher G&A costs for commercial planning.
- The company may seek additional capital through partnerships or licensing, business combinations, debt, or equity. Financing may not be available on acceptable terms; equity could dilute stockholders, debt could impose payment obligations and covenants, and collaborations could reduce product economics. Failure to obtain funding could delay or discontinue development programs or trials.
- Key risks include clinical safety and efficacy outcomes, trial timing and cost, regulatory approval, manufacturing and clinical-service availability, competition, intellectual-property challenges, and the ability to fund development and commercialization. Early-stage trial results may not predict later-stage success.
- A new New Jersey office and laboratory lease covers approximately 33,000 square feet for five years and five months, with annual rent increasing from $0.4 million in year one to $0.5 million in year five; rent begins five months after lease commencement. No legal proceedings were reported, and the filing stated there were no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether ACT IV and planned CDX-011 METRIC milestones proceeded on schedule, and the eventual clinical results and regulatory implications.
- Actual cash burn, investment maturities, and the assumptions supporting management’s stated funding horizon, particularly given the different “at least 12 months” and “through 2015” statements.
- Future financing needs, dilution, and any partnership or licensing terms; also confirm remaining availability under the Cantor facility, reported as $4.4 million at June 30, 2013.
- How the end of Rotarix-related royalties affects future revenue and whether operating expenses continue to rise as projected.
- Potential lease costs and other commitments, and the timing and amount of any clinical-trial milestone or manufacturing obligations.